Anthony King
I am a freelance science journalist based in Dublin, Ireland. I cover a variety of topics in chemical and biological sciences, as well as science policy, health and innovation.
My articles have appeared in Nature, Science, Cell, Chemistry World, New Scientist, the Irish Times, New York Times, EMBO Reports, Chemistry & Industry and more.
I enjoy writing on a wide breadth of subjects, from antibiotics to petrochemicals, bumblebees to asteroid composition, palaeontology to brain development. Previously I worked for a publishing company as a science editor.
My primary degree in science is from Trinity College Dublin and I hold a Master’s degree in science communications from Dublin City University.
ResearchTherapeutic proteins can hitch a ride on parasite to bypass blood-brain barrier
Toxoplasma could be delivery agent for protein drugs – provided parasite can be made safe
NewsWeight-loss drugmakers bet billions on boosting supplies
Eli Lilly and Novo Nordisk invest to expand in-house manufacturing of GLP-1 drugs
NewsMetallic nodules sought by deep sea miners could be making oxygen in the depths
Water-splitting at the bottom of the Pacific holds intriguing implications for the origin of life on Earth – and further afield
ResearchNew gene-editing tool found in bacterium could carry out extensive genome remodelling
Highly selective mechanism can insert, remove and flip large portions of DNA
NewsNineteen journals shut down by Wiley following delisting and paper mill problems
Issues with manufactured manuscripts are a problem the whole publishing industry faces
NewsFour new research centres launched with €104 million from Science Foundation Ireland
Advanced manufacturing, neurological disease and bioeconomy concept to support 600 roles
BusinessPan-cancer approval shows huge potential for antibody–drug conjugates
Enhertu gains approval based on gene expression rather than tumour location
ResearchHow HIV drugs have changed over the decades
From one big pill that only prolonged lives a few months, through the 20 pills a day years to modern combination therapies, treating HIV is a science success story
ResearchMicrobial enzymes cut a path towards universal blood for transfusions
Slicing off glycans revealed new, previously unknown antigens that must be removed to produce O-type blood
NewsPlastic chemicals review reveals thousands of compounds have little safety data
Existing scientific knowledge on hazards of plastic chemicals compiled in dossier for decision makers
ResearchConcerns raised over health effects of chemicals leaching from food packaging
Gene assays reveal disruption to cell receptors crucial for hormonal and metabolic control
FeatureHow microbes influence our brain health
Our gut microbiome has been linked to conditions such as Parkinson’s and Alzheimer’s. Anthony King reports on the connections
BusinessChemours suspends chief and senior executives over accounting issues
Auditors to investigate issues around whistleblowing and financial management
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
ResearchStriking reptilian fossil discovered in 1931 found to be fake
280-million-year-old lizard ‘fossil’ was mostly painted on
BusinessNovo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
ResearchRare medical transmission of Alzheimer’s disease from donor to patient discovered
Human growth hormone extracted from cadavers passed disease protein to at least five people
BusinessNuclear power expansion plans highlight fuel bottlenecks
Western governments look to overcome Russian dominance of key uranium processing steps
BusinessDanaher completes $5.7 billion Abcam acquisition
Deal proceeded despite significant opposition from founder and ex-chief Jonathan Milner